Date:6/18/2012

a focus on the development of prescription drugs that target unmet medical needs. Debiopharm in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm, please visit: http://www.debiopharm.com

About Ascepion Pharmaceuticals

Based in Suzhou, China, Ascepion Pharmaceuticals, Inc. is a leading biopharmaceutical company in China dedicated to the discovery and development of breakthrough small molecule drugs. Ascepion Pharmaceuticals possesses a fully integrated platform and proprietary technologies for the discovery and development of small molecule therapeutics targeting signal transduction pathways in a systematic and productive manner. The company has developed a pipeline of innovative small molecule drugs for the treatment of oncology and related diseases. For additional information on Ascepion Pharmaceuticals, please visit the company's website at http://www.ascepion.com .

    
    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)
'/>"/>

SOURCE The Debiopharm Group and Ascepion Pharmaceuticals Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
4. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan